


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:


1. (previously presented). A compound of formula (I):



(I)

wherein

A is a fused 5-membered heteroaryl ring selected from:



which ring is optionally substituted by up to two substituents independently selected from C₁₋₆alkyl, -(CH₂)_m-C₃₋₇cycloalkyl, halogen, cyano, trifluoromethyl, -(CH₂)_mOR³, -(CH₂)_mCO₂R³, -(CH₂)_mNR³R⁴, -(CH₂)_mCONR³R⁴, -(CH₂)_mNHCOR³, -(CH₂)_mSO₂NR³R⁴, -(CH₂)_mNHSO₂R³, -(CH₂)_mSO₂(CH₂)_nR⁵, a 5- or 6-membered heterocyclyl ring containing nitrogen optionally substituted by C₁₋₂alkyl or -(CH₂)_mCO₂R³, and a 5-membered heteroaryl ring optionally substituted by C₁₋₂alkyl;

R¹ is selected from methyl and chloro;

R² is selected from -NH-CO-R⁶ and -CO-NH-(CH₂)_q-R⁷;

R^3 is selected from hydrogen, C_{1-6} alkyl optionally substituted by up to two OH groups, $-(CH_2)_m-C_{3-7}$ cycloalkyl, $-(CH_2)_m$ phenyl optionally substituted by R^8 and/or R^9 and $-(CH_2)_m$ heteroaryl optionally substituted by R^8 and/or R^9 ;

R^4 is selected from hydrogen and C_{1-6} alkyl, or

R^3 and R^4 , together with the nitrogen atom to which they are bound, form a 5- or 6-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and N- R^{10} ;

R^5 is selected from C_{1-6} alkyl optionally substituted by up to three halogen atoms, C_{2-6} alkenyl optionally substituted by phenyl, C_{3-7} cycloalkyl, heteroaryl optionally substituted by up to three R^8 and/or R^9 groups, and phenyl optionally substituted by R^8 and/or R^9 ;

R^6 is selected from hydrogen, C_{1-6} alkyl, $-(CH_2)_q-C_{3-7}$ cycloalkyl, trifluoromethyl, $-(CH_2)_r$ heteroaryl optionally substituted by R^{11} and/or R^{12} , and $-(CH_2)_r$ phenyl optionally substituted by R^{11} and/or R^{12} ;

R^7 is selected from hydrogen, C_{1-6} alkyl, C_{3-7} cycloalkyl, $-CONHR^{13}$, phenyl optionally substituted by R^{11} and/or R^{12} , and heteroaryl optionally substituted by R^{11} and/or R^{12} ;

R^8 and R^9 are each independently selected from halogen, cyano, trifluoromethyl, nitro, C_{1-6} alkyl, C_{1-6} alkoxy, $-CONR^{13}R^{14}$, $-COR^{15}$, $-CO_2R^{15}$, and heteroaryl, or

R^8 and R^9 are linked to form a fused 5-membered heterocyclyl ring containing one heteroatom selected from oxygen, sulphur and N- R^{10} , or a fused heteroaryl ring;

R^{10} is selected from hydrogen and methyl;

R^{11} is selected from C_{1-6} alkyl,

C_{1-6} alkoxy, $-(CH_2)_q-C_{3-7}$ cycloalkyl, $-CONR^{13}R^{14}$, $-NHCOR^{14}$, halogen, CN, $-(CH_2)_sNR^{16}R^{17}$, trifluoromethyl, phenyl optionally substituted by one or more R^{12} groups, and heteroaryl optionally substituted by one or more R^{12} groups;

R^{12} is selected from C_{1-6} alkyl, C_{1-6} alkoxy, halogen, trifluoromethyl, and $-(CH_2)_sNR^{16}R^{17}$;

R^{13} and R^{14} are each independently selected from hydrogen and C_{1-6} alkyl, or

R^{13} and R^{14} , together with the nitrogen atom to which they are bound, form a 5- or 6-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and N- R^{10} , wherein the ring may be substituted by up to two C_{1-6} alkyl groups;

R^{15} is C_{1-6} alkyl;

R^{16} is selected from hydrogen, C_{1-6} alkyl and $-(CH_2)_q-C_{3-7}$ cycloalkyl optionally substituted by C_{1-6} alkyl,

R^{17} is selected from hydrogen and C_{1-6} alkyl, or

R^{16} and R^{17} , together with the nitrogen atom to which they are bound, form a 5- or 6-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and N- R^{10} ;

X and Y are each independently selected from hydrogen, methyl and halogen;

m is selected from 0, 1, 2 and 3;

n is selected from 0, 1, 2 and 3;

q is selected from 0, 1 and 2;

r is selected from 0 and 1; and

s is selected from 0, 1, 2 and 3.

2 (Currently amended). A compound according to claim 1 wherein the A ring is optionally substituted by up to two substituents independently selected from C_{1-4} alkyl, $-(CH_2)_m-C_{3-7}$ cycloalkyl, $-(CH_2)_mCO_2R^3$, $-(CH_2)_mNR^3R^4$, -

$(CH_2)_mCONR^3R^4$, $-(CH_2)_mNHCOR^3$, $-(CH_2)_mSO_2(CH_2)_nR^5$, and a 5- or 6-membered heterocyclyl ring containing nitrogen optionally substituted by C_{1-2} alkyl or $-(CH_2)_mCO_2R^3$.

3 (previously presented). A compound according to claim 1 wherein R^1 is methyl.

4 (previously presented). A compound according to claim 1 wherein R^2 is $-CO-NH-(CH_2)_q-R^7$.

5 (previously presented). A compound according to claim 1 wherein X is hydrogen or fluorine.

6 (previously presented). A compound according to claim 1 which is:

N-Cyclopropyl-4-methyl-3-(3-piperidin-4-yl-1,2-benzisoxazol-6-yl)benzamide;

4-Methyl-N-(3-morpholin-4-ylphenyl)-3-(3-piperidin-4-yl-1,2-benzisoxazol-6-yl)benzamide;

N-[4-Methyl-3-(3-piperidin-4-yl-1,2-benzisoxazol-6-yl)phenyl]-2-pyrrolidin-1-ylisonicotinamide;

N-[4-Methyl-3-(3-methyl-1,2-benzisoxazol-6-yl)phenyl]-2-pyrrolidin-1-ylisonicotinamide;

N-[4-Methyl-3-(3-methyl-1,2-benzisoxazol-6-yl)phenyl]thiophene-3-carboxamide;

N-[4-Methyl-3-(3-methyl-1,2-benzisoxazol-6-yl)phenyl]-3-furamide;

4-Methyl-3-(3-methyl-1,2-benzisoxazol-6-yl)-N-(3-morpholin-4-ylphenyl)benzamide;

4-Methyl-3-(3-methyl-1,2-benzisoxazol-6-yl)-N-(1,3-thiazol-2-yl)benzamide;

N-Cyclopropyl-4-methyl-3-(3-methyl-1,2-benzisoxazol-6-yl)benzamide;


or a pharmaceutically acceptable salt thereof.

7 (previously presented). A pharmaceutical composition comprising a compound according to claim 1 in admixture with one or more pharmaceutically acceptable carriers, diluents or excipients.

8. - 9. (Cancelled)


10 (previously presented). A process for preparing a compound of formula (I) according to claim 1 which comprises

(a) reacting a compound of formula (II)




(II)

in which A is defined in claim 1 and Z¹ is halogen,
with a compound of formula (IIIA) or (IIIB)



(IIIA)




(IIIB)

in which R¹, R², X and Y are as defined in claim 1,
in the presence of a catalyst, or

(b) final stage modification of one compound of formula (I) as defined in claim 1 to
give another compound of formula (I) as defined in claim 1.


11 (previously presented). A compound of formula (IA):



(IA)

wherein

A is a fused 5-membered heteroaryl ring selected from:



which ring is optionally substituted by up to two substituents independently selected from C_{1-6} alkyl, $-(CH_2)_m-C_{3-7}$ cycloalkyl, halogen, cyano, trifluoromethyl, $-(CH_2)_mOR^3$, $-(CH_2)_mNR^3R^4$, $-(CH_2)_mCONR^3R^4$, $-(CH_2)_mNHCOR^3$, $-(CH_2)_mSO_2NR^3R^4$, $-(CH_2)_mNHSO_2R^3$, $-(CH_2)_mSO_2(CH_2)_nR^5$, a 5- or 6-membered heterocyclyl ring containing nitrogen optionally substituted by C_{1-2} alkyl and a 5-membered heteroaryl ring optionally substituted by C_{1-2} alkyl;

R^1 is selected from methyl and chloro;

R^2 is selected from $-NH-CO-R^6$ and $-CO-NH-(CH_2)_q-R^7$;

R^3 is selected from hydrogen, C_{1-6} alkyl optionally substituted by up to two OH groups, $-(CH_2)_m-C_{3-7}$ cycloalkyl, $-(CH_2)_m$ phenyl optionally substituted by R^8 and/or R^9 and $-(CH_2)_m$ heteroaryl optionally substituted by R^8 and/or R^9

R^4 is selected from hydrogen and C_{1-6} alkyl, or

R^3 and R^4 , together with the nitrogen atom to which they are bound, form a 5- or 6-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and $N-R^{10}$;

R^5 is selected from C_{1-6} alkyl, C_{3-7} cycloalkyl, heteroaryl optionally substituted by R^8 and/or R^9 , and phenyl optionally substituted by R^8 and/or R^9 ;

R^6 is selected from hydrogen, C_{1-6} alkyl, $-(CH_2)_q-C_{3-7}$ cycloalkyl, trifluoromethyl, $-(CH_2)_r$ heteroaryl optionally substituted by R^{11} and/or R^{12} , and $-(CH_2)_r$ phenyl optionally substituted by R^{11} and/or R^{12} ;

R^7 is selected from hydrogen, C_{1-6} alkyl, C_{3-7} cycloalkyl, $CONHR^{13}$, phenyl optionally substituted by R^{11} and/or R^{12} , and heteroaryl optionally substituted by R^{11} and/or R^{12} ;

R^8 and R^9 are each independently selected from halogen, cyano, trifluoromethyl, C_{1-6} alkyl, C_{1-6} alkoxy, COR^{15} , CO_2R^{15} , and heteroaryl, or

R^8 and R^9 are linked to form a fused 5-membered heterocyclyl ring containing one heteroatom selected from oxygen, sulphur and $N-R^{10}$;

R¹⁰ is selected from hydrogen and methyl;

R¹¹ is selected from C₁₋₆alkyl, C₁₋₆alkoxy, -(CH₂)_q-C₃₋₇cycloalkyl, -CONR¹³R¹⁴, -NHCOR¹⁴, halogen, CN, -(CH₂)_sNR¹⁶R¹⁷, trifluoromethyl, phenyl optionally substituted by one or more R¹² groups, and heteroaryl optionally substituted by one or more R¹² groups;

R¹² is selected from C₁₋₆alkyl, C₁₋₆alkoxy, halogen, trifluoromethyl, and -(CH₂)_sNR¹⁶R¹⁷;

R¹³ and R¹⁴ are each independently selected from hydrogen and C₁₋₆alkyl, or

R¹³ and R¹⁴, together with the nitrogen atom to which they are bound, form a 5- or 6-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and N-R¹⁰, wherein the ring may be substituted by up to two C₁₋₆alkyl groups;

R¹⁵ is C₁₋₆alkyl;

R¹⁶ is selected from hydrogen, C₁₋₆alkyl and -(CH₂)_q-C₃₋₇cycloalkyl optionally substituted by C₁₋₆alkyl,

R¹⁷ is selected from hydrogen and C₁₋₆alkyl, or

R¹⁶ and R¹⁷, together with the nitrogen atom to which they are bound, form a 5- or 6-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and N-R¹⁰;

m is selected from 0, 1, 2 and 3;

n is selected from 0, 1, 2 and 3;

q is selected from 0, 1 and 2;

r is selected from 0 and 1; and

s is selected from 0, 1, 2 and 3.

12 (Previously presented). A compound according to claim 1 which is:

N-[4-methyl-3-(3-piperidin-4-yl-1,2-benzisoxazol-6-yl)phenyl]-2-pyrrolidin-1-ylisonicotinamide; N-cyclopropyl-4-methyl-3-[3-(4-morpholinyl)-1,2-benzisoxazol-6-yl]benzamide;
N-cyclopropyl-4-methyl-3-{3-[2-oxo-2-(1,3-thiazol-2-ylamino)ethyl]-1,2-benzisoxazol-6-yl}benzamide;
N-cyclopropyl-4-methyl-3-[3-(4-morpholinylmethyl)-1,2-benzisoxazol-6-yl]benzamide;
N-cyclopropyl-4-methyl-3-[3-(1-pyrrolidinylmethyl)-1,2-benzisoxazol-6-yl]benzamide;
or a pharmaceutically acceptable salt thereof.

13. – 14. (cancelled)

15. (withdrawn). A compound according to claim 1 which is:

N-[4-Methyl-3-(3-methyl-1,2-benzisoxazol-5-yl)phenyl]-2-pyrrolidin-1-ylisonicotinamide;

N-Cyclopropyl-3-[3-({[2-hydroxy-1-(hydroxymethyl)ethyl]amino} methyl)-1,2-benzisoxazol-6-yl]-4-methylbenzamide;

N-(3-Methoxyphenyl)-4-methyl-3-(3-piperidin-4-yl-1,2-benzisoxazol-6-yl)benzamide;

4-Methyl-3-(3-piperidin-4-yl-1,2-benzisoxazol-6-yl)-N-(1,3,4-thiadiazol-2-yl)benzamide;

N-[4-Methyl-3-(3-piperidin-4-yl-1,2-benzisoxazol-6-yl)phenyl]thiophene-3-carboxamide;

N-[4-Methyl-3-(3-piperidin-4-yl-1,2-benzisoxazol-6-yl)phenyl]-3-furamide;

N-(Cyclopropylmethyl)-4-methyl-3-(3-piperidin-4-yl-1,2-benzisoxazol-6-yl)benzamide;

or a pharmaceutically acceptable salt thereof.

16. (cancelled)

17. (withdrawn) A compound according to Claim 1 which is

4-Methyl-3-(3-piperidin-4-yl-1,2-benzisoxazol-6-yl)-N-(1,3-thiazol-2-yl)benzamide;

N-Cyclopropyl-4-methyl-3-[3-(1-piperazinyl)-1,2-benzisoxazol-6-yl]benzamide;

N-Cyclopropyl-4-methyl-3-[3-(4-morpholinyl)-1,2-benzisoxazol-6-yl]benzamide;

N-Cyclopropyl-4-methyl-3-{3-[2-oxo-2-(1-piperazinyl)ethyl]-1,2-benzisoxazol-6-yl}benzamide;

Methyl (6-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-1,2-benzisoxazol-3-yl)acetate;

N-Cyclopropyl-3-(3-{2-[(2-hydroxyethyl)amino]-2-oxoethyl}-1,2-benzisoxazol-6-yl)-4-methylbenzamide;

N-Cyclopropyl-4-methyl-3-{3-[2-oxo-2-(1-piperidinyl)ethyl]-1,2-benzisoxazol-6-yl}benzamide;

N-Cyclopropyl-4-methyl-3-{3-[2-(methylamino)-2-oxoethyl]-1,2-benzisoxazol-6-yl}benzamide;

N-Cyclopropyl-3-(3-{2-[(3-hydroxypropyl)amino]-2-oxoethyl}-1,2-benzisoxazol-6-yl)-4-methylbenzamide;

N-Cyclopropyl-3-(3-{2-[(cyclopropylmethyl)amino]-2-oxoethyl}-1,2-benzisoxazol-6-yl)-4-methylbenzamide;

N-Cyclopropyl-4-methyl-3-{3-[2-oxo-2-(1-pyrrolidinyl)ethyl]-1,2-benzisoxazol-6-yl}benzamide;

N-Cyclopropyl-3-{3-[2-(ethylamino)-2-oxoethyl]-1,2-benzisoxazol-6-yl}-4-methylbenzamide;

N-Cyclopropyl-3-{3-[2-(cyclopropylamino)-2-oxoethyl]-1,2-benzisoxazol-6-yl}-4-methylbenzamide;

N-Cyclopropyl-4-methyl-3-{3-[2-(4-morpholinyl)-2-oxoethyl]-1,2-benzisoxazol-6-yl}benzamide;

N-Cyclopropyl-4-methyl-3-{3-[2-({[3-(methyloxy)phenyl]methyl}amino)-2-oxoethyl]-1,2-benzisoxazol-6-yl}benzamide;

N-Cyclopropyl-4-methyl-3-{3-[2-oxo-2-(1,3-thiazol-2-ylamino)ethyl]-1,2-benzisoxazol-6-yl}benzamide;

N-Cyclopropyl-4-methyl-3-{3-[(4-methyl-1-piperazinyl)methyl]-1,2-benzisoxazol-6-yl}benzamide;

N-Cyclopropyl-4-methyl-3-[3-(1-piperidinylmethyl)-1,2-benzisoxazol-6-yl]benzamide;

N-Cyclopropyl-4-methyl-3-[3-(4-morpholinylmethyl)-1,2-benzisoxazol-6-yl]benzamide;

N-Cyclopropyl-4-methyl-3-[3-(1-pyrrolidinylmethyl)-1,2-benzisoxazol-6-yl]benzamide;

3-(3-Amino-1,2-benzisoxazol-6-yl)-N-cyclopropyl-4-methylbenzamide;

N-Cyclopropyl-3-[3-(cyclopropylamino)-1,2-benzisoxazol-6-yl]-5-fluoro-4-methylbenzamide;

6-{5-[(Cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl}-N-(cyclopropylmethyl)-1,2-benzisoxazole-3-carboxamide;

6-{5-[(Cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl}-N-propyl-1,2-benzisoxazole-3-carboxamide;

6-{5-[(Cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl}-N-methyl-1,2-benzisoxazole-3-carboxamide;

6-{5-[(Cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl}-N,N-dimethyl-1,2-benzisoxazole-3-carboxamide;

N-Cyclopropyl-6-{5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl}-1,2-benzisoxazole-3-carboxamide;

N-Cyclopropyl-3-fluoro-4-methyl-5-{1-[(4-methylphenyl)sulfonyl]-1H-indol-5-yl}benzamide;

N-Cyclopropyl-3-fluoro-4-methyl-5-[1-(phenylsulfonyl)-1H-indol-5-yl]benzamide;

N-Cyclopropyl-3-{2-[(cyclopropylcarbonyl)amino]-1,3-benzothiazol-6-yl}-4-methylbenzamide; or a pharmaceutically acceptable salt thereof.

18. 19. (cancelled)

20. (Previously presented) A pharmaceutical composition comprising a compound according to claim 6 in admixture with one or more pharmaceutically acceptable carriers, diluents or excipients.

21. (Previously presented) A pharmaceutical composition comprising a compound according to claim 12 in admixture with one or more pharmaceutically acceptable carriers, diluents or excipients.

22. (Previously presented) A pharmaceutical composition comprising a compound according to claim 15 in admixture with one or more pharmaceutically acceptable carriers, diluents or excipients.

23. (cancelled)

24. (Previously presented) A pharmaceutical composition comprising a compound according to claim 17 in admixture with one or more pharmaceutically acceptable carriers, diluents or excipients.

25. -26 (cancelled)